These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23591988)

  • 1. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.
    Schwartz GL; Bailey K; Chapman AB; Boerwinkle E; Turner ST
    Am J Hypertens; 2013 Aug; 26(8):957-64. PubMed ID: 23591988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.
    Gharaibeh KA; Turner ST; Hamadah AM; Chapman AB; Cooper-Dehoff RM; Johnson JA; Gums JG; Bailey KR; Schwartz GL
    Am J Hypertens; 2016 Oct; 29(10):1186-94. PubMed ID: 27365079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.
    Weintraub HS; Duprez DA; Cushman WC; Zappe DH; Purkayastha D; Samuel R; Izzo JL
    Cardiovasc Drugs Ther; 2012 Apr; 26(2):145-55. PubMed ID: 22311004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.
    Canzanello VJ; Baranco-Pryor E; Rahbari-Oskoui F; Schwartz GL; Boerwinkle E; Turner ST; Chapman AB
    Am J Hypertens; 2008 Jan; 21(1):61-6. PubMed ID: 18091745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
    Turner ST; Bailey KR; Schwartz GL; Chapman AB; Chai HS; Boerwinkle E
    Hypertension; 2012 Jun; 59(6):1204-11. PubMed ID: 22566498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of renin levels on the treatment of essential hypertension with thiazide diuretics.
    Wyndham RN; Gimenez L; Walker WG; Whelton PK; Russell RP
    Arch Intern Med; 1987 Jun; 147(6):1021-5. PubMed ID: 3296978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
    Cushman WC; Bakris GL; White WB; Weber MA; Sica D; Roberts A; Lloyd E; Kupfer S
    Hypertension; 2012 Aug; 60(2):310-8. PubMed ID: 22710649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma renin activity for predicting antihypertensive drug efficacy.
    Blumenfeld JD
    Am J Hypertens; 2008 Jan; 21(1):5-6. PubMed ID: 18091734
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial.
    Association of Black Cardiologists (ABC) Candesartan Study Group
    Heart Dis; 2000; 2(6):392-9. PubMed ID: 11728289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
    Mengden T; Uen S; Bramlage P
    Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
    Mugellini A; Nieswandt V
    Expert Opin Pharmacother; 2012 Dec; 13(18):2699-709. PubMed ID: 23170938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
    Volpe M; Tocci G
    Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
    Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
    MMW Fortschr Med; 2008 Feb; 150(6):40. PubMed ID: 18323344
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.
    Pais P; Jung H; Dans A; Zhu J; Liu L; Kamath D; Bosch J; Lonn E; Yusuf S
    Eur J Prev Cardiol; 2019 May; 26(7):681-697. PubMed ID: 30537846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.
    Bakris GL; Smith DH; Giles TD; White WB; Davidai G; Weber MA
    J Clin Hypertens (Greenwich); 2005 Oct; 7(10):587-95; quiz 596-7. PubMed ID: 16227761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
    Turner ST; Schwartz GL; Chapman AB; Beitelshees AL; Gums JG; Cooper-DeHoff RM; Boerwinkle E; Johnson JA; Bailey KR
    Am J Hypertens; 2010 Sep; 23(9):1014-22. PubMed ID: 20725057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
    Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
    J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.